Rheumatic Diseases

The supplied grounding does not support a single cause for rheumatic diseases as a group. The literature instead emphasizes immune dysregulation and chronic inflammation across multiple rheumatic conditions.

The grounding supports a shared inflammatory and immune-mediated biology across rheumatic diseases. In particular, dysregulation of the IL-23/IL-17 axis is described as promoting Th17-cell activation and downstream production of pro-inflammatory mediators such as IL-17A, IL-17F, IL-6, IL-22, and TNF-α, contributing to chronic immune-mediated inflammation and tissue damage. The abstracts also describe autoreactive B cells and broader immune dysregulation as relevant mechanisms in autoimmune rheumatic diseases.

The supplied grounding does not identify general risk factors for rheumatic diseases as a category. One abstract notes that patients with preexisting rheumatologic autoimmune disease are a distinct population in the context of immune checkpoint inhibitor therapy, but this is not presented as a general disease risk factor.

The grounding supports treatment at the modality and drug-class level rather than a single standard regimen. It mentions inflammatory pathways as therapeutic targets, existing B-cell depletion therapies, immune checkpoint inhibitors in patients with preexisting rheumatologic autoimmune disease, and emerging chimeric antigen receptor T-cell therapy, including CD19-targeting CAR constructs for refractory autoimmune rheumatic diseases. It does not provide enough support to define one uniform standard of care across all rheumatic diseases.